Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2017
Reporting Period: Quarter ended March 31, 2017
Context: The filing announces the financial results for the quarter ended March 31, 2017. The detailed results are contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided text serves as a cover document referencing the press release (Exhibit 99.1) for specific data. Consequently, the filing text does not provide clear values for the following metrics:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt
- Liquidity
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are located within the referenced press release (Exhibit 99.1).
Important Facts for Investor Verification
- Verify the specific financial figures (revenue, net loss, cash position) in the attached press release (Exhibit 99.1) as they are not listed in the 8-K body.
- Confirm the company's status as an "Emerging Growth Company" and its election not to use the extended transition period for new accounting standards.
- Note that the information in this 8-K is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for the forward-looking statements contained in the referenced exhibit.